Researchers at Huazhong Agricultural University began by asking whether the human gut microbiota as a whole could degrade licochalcone A. They recruited four healthy young Chinese men aged 24 to 27, excluding anyone with recent antibiotic use, probiotic consumption, gastrointestinal disorders, or metabolic disease, and collected fresh fecal samples that were processed entirely inside an anaerobic chamber to preserve the viability of oxygen-sensitive microbes. Each donor’s microbiota was then cultured in broth supplemented with licochalcone A and monitored for 48 hours. The results revealed striking interindividual variability: the most efficient community, from Donor A, degraded roughly 55 percent of the compound, while the least efficient, from Donor C, managed only about 27 percent. This spread matters, because it suggests that two people eating the same licorice-containing diet could experience substantially different exposure to the parent compound and its microbial derivatives.

The fermentation experiments produced a second, equally important observation. When licochalcone A was present, microbial biomass grew more vigorously than in controls, with optical density readings at 24 hours reaching 0.83 compared with 0.52 in untreated cultures, and the pH of the cultures dropped to around 5.5 versus roughly 6.4 in controls, a highly significant difference. Lower intestinal pH is generally considered a hallmark of a healthier microbial environment, favoring beneficial commensals while suppressing opportunistic pathogens. Gas chromatography–mass spectrometry confirmed the metabolic significance of this shift: concentrations of acetic, propionic, butyric, and isobutyric acids all rose significantly after 24 hours, with propionate and butyrate showing the most pronounced increases. These short-chain fatty acids are among the most consequential metabolites the gut microbiota produces, fueling colonocytes, reinforcing the intestinal barrier, enhancing insulin sensitivity, and exerting anti-inflammatory effects throughout the body.

Using liquid chromatography coupled with tandem mass spectrometry, the team then hunted for the chemical fingerprints of microbial transformation. Licochalcone A displays a protonated molecular ion at m/z 339.1; after 48 hours of anaerobic fermentation, a new ion appeared at m/z 355.2, a mass increase of 16 daltons that pointed to a single hydroxylation event. The new metabolite eluted slightly earlier than the parent compound, consistent with its increased polarity, and comparison with an authentic reference standard of 3-hydroxylicochalcone A confirmed matching retention time and fragmentation patterns. Remarkably, this metabolite, abbreviated 3-HLA, appeared consistently across all four donors, suggesting that the transformation is mediated by a conserved microbial capability rather than a quirk of one person’s microbiome. Because many dietary polyphenols must be converted by gut bacteria before they can reach systemic circulation, the identification of 3-HLA establishes microbial metabolism as an additional regulatory layer governing the bioavailability and physiological impact of licochalcone A.

With community-level degradation established, the researchers turned to the strain level. Seventeen bacterial species were randomly isolated from human fecal samples, deliberately without pre-selecting for degradation ability, and each was challenged with licochalcone A under anaerobic conditions. Degradation capacity varied enormously. Escherichia coli, Collinsella aerofaciens, Clostridium innocuum, and Clostridium butyricum all performed respectably, removing roughly 80 to 88 percent of the compound, while Enterococcus faecium, Enterococcus faecalis, and Bacteroides vulgatus managed less than 25 percent. But the standout was Bifidobacterium longum subsp. suillum, a subspecies never before implicated in natural product degradation and, according to the authors, never previously isolated from human feces in the context of chalcone metabolism. Strain AA-55, as the isolate is designated, degraded approximately 90 percent of licochalcone A within 48 hours, and its growth actually accelerated during the exponential phase when the compound was present.

To understand how this bacterium accomplishes the feat, the team sequenced its entire genome. The circular chromosome of strain AA-55 spans 2,250,570 base pairs with a G+C content of 59.76 percent and encodes 1,841 proteins, along with five CRISPR loci and a compact set of RNA genes. Functional annotation revealed substantial enrichment of genes associated with xenobiotic biodegradation and metabolism, secondary metabolite biosynthesis and catabolism, and oxidoreductase catalytic activity, all categories consistent with a capacity to chemically transform structurally diverse exogenous compounds. The genome also carries 71 carbohydrate-active enzymes, including 45 glycoside hydrolases and 14 glycosyltransferases. The authors are careful to note, however, that genomic annotation alone cannot prove which enzymes perform the hydroxylation; genetic knockouts, enzyme purification, and heterologous expression studies will be needed to pin down the exact molecular machinery.

Untargeted metabolomics added a dynamic dimension to the story. When cultures of strain AA-55 were exposed to licochalcone A and sampled at 0, 6, and 24 hours, principal component and discriminant analyses showed complete metabolic segregation between exposed and control groups, with the first two principal components explaining over 62 percent of the variance. At 6 hours, 227 metabolites were significantly upregulated and 582 downregulated; by 24 hours the figures were 280 and 675. Pathway enrichment centered on amino acid metabolism, nucleotide turnover, the TCA cycle, and ABC transporters, indicating that degrading licochalcone A is not an isolated enzymatic side reaction but a process woven into the bacterium’s broader metabolic reprogramming. Among the altered metabolites were glycoisoflavanone, licoagroside B, and deoxyphomalone, compound classes previously associated with biological activity, though their specific health effects remain uncharacterized.

Perhaps the most ecologically intriguing finding came from co-culture experiments. Akkermansia muciniphila and Bacteroides ovatus, two species of considerable interest in gut health research, could barely degrade licochalcone A on their own. But when the researchers grew them in culture supernatant harvested from strain AA-55 fermenting the compound, both species proliferated dramatically, with 2.3-fold and 3-fold increases in growth respectively compared with vehicle-conditioned medium. In other words, the primary degrader’s metabolic byproducts function as cross-feeding currency that sustains secondary consumers, echoing the well-documented prebiotic behavior of inulin and fructooligosaccharides, where fiber-fermenting pioneers feed the rest of the community. This positions licochalcone A not merely as a pharmacological flavonoid but as a potential prebiotic-like ecological modulator capable of reshaping gut community structure through cooperative metabolism.

In vivo validation in mice lent the laboratory findings physiological weight. Oral administration of licochalcone A at 50 milligrams per kilogram to conventional C57BL/6 mice, followed by 16S rRNA gene sequencing of fecal samples at baseline, 6, 24, and 48 hours, revealed transient shifts in microbial composition: Bacteroidota rose at 6 and 24 hours while Bacillota dipped early, and taxa including Dubosiella, Allobaculum, and Bifidobacterium increased in relative abundance at later time points. These results align with earlier reports that licochalcone A promotes beneficial taxa in models of colitis and type 2 diabetes, though the authors caution that the dose used here exceeds typical human dietary exposure and that the absence of a vehicle-gavage control leaves room for handling effects.

The study’s limitations are candidly acknowledged: the human cohort comprised only four young men, the co-culture system simplifies the gut’s ecological complexity, and the biological function of 3-HLA in the body remains to be demonstrated. Even so, the work marks a genuine advance, revealing for the first time that bifidobacteria can drive chalcone biotransformation and identifying a specific strain whose metabolic appetite may determine how much active compound, and which derivatives, a licorice lover actually absorbs. As interest in microbiota-targeted functional foods accelerates, knowing which gut residents process licochalcone A, and how their activity ripples through the microbial food web, could prove essential for designing interventions that harness licorice’s ancient therapeutic promise with modern precision.

Subject of Research: Microbial degradation and biotransformation of the licorice flavonoid licochalcone A by the human gut microbiota

Article Title: Degradation and biotransformation of Licochalcone A by the human gut microbiota: Role of Bifidobacterium longum subsp . Suillum AA-55

Article References: Degradation and biotransformation of Licochalcone A by the human gut microbiota: Role of Bifidobacterium longum subsp . Suillum AA-55. (n.d.). https://doi.org/10.1016/j.jafr.2026.103299

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103299

Keywords: licochalcone A, gut microbiota, Bifidobacterium longum, licorice, 3-hydroxylicochalcone A, biotransformation, short-chain fatty acids, cross-feeding, polyphenols, metabolomics, prebiotic, functional foods

The research, carried out by an international team working across institutes in Iran and Germany, including the Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) in Gatersleben and Shiraz University, took on one of the most persistent challenges in medicinal plant science: connecting visible chemical traits to the underlying genetic code. The team genotyped 175 accessions and populations spanning the genus Glycyrrhiza using genotyping-by-sequencing, a technique that slashes the cost of genome-wide profiling by sequencing only the most informative slices of DNA. From this effort they assembled a catalogue of 38,393 high-quality single-nucleotide polymorphisms, or SNPs—individual letter changes scattered across the genome that serve as signposts for comparative genetics.

The first major finding concerns how licorice species relate to one another. Genetic structure analysis showed that G. glabra, the species that produces the celebrated medicinal root, is mostly distinct from its relatives in the genus. This genetic separation matters for conservationists and breeders alike, because it indicates that G. glabra carries a unique reservoir of variation that cannot simply be recovered from closely related species. Within G. glabra itself, the analysis identified a coherent group of 66 plants drawn from 33 Iranian origins, showing moderate genetic differentiation from other accessions. Iran, with its long tradition of licorice harvesting and its position at the heart of the plant’s natural range, appears to shelter a genetically recognizable and potentially valuable portion of the species’ diversity.

With the population structure established, the researchers turned to the central question: which genomic regions control the accumulation of the plant’s bioactive metabolites? They focused on three medically important traits and deployed genome-wide association mapping, a statistical approach that scans thousands of SNPs for correlations with measured phenotypes across many individuals. The results were striking. Twenty highly significant SNP associations emerged in total. Fifteen of them were linked to glabridin in the cork layer of the root, and three of those were also associated with glabridin in the fleshy texture of the root. Five additional SNPs were associated with liquiritigenin in the cork layer.

Those two compounds deserve attention on their own terms. Glabridin is the signature flavonoid of licorice, prized for anti-inflammatory, skin-brightening, antioxidant, and antimicrobial properties, and it is a staple ingredient in cosmetic and pharmaceutical pipelines worldwide. Liquiritigenin is another flavonoid with documented pharmacological activity and a key position in the flavonoid biosynthetic pathway of the plant. Intriguingly, both molecules are described as players in biotic and abiotic stress responses, meaning the plant likely deploys them as chemical shields against pathogens and harsh environmental conditions. The new genetic associations suggest that the very loci breeders might select for higher medicinal content are also tied to how robustly the plant defends itself—a potentially powerful linkage for developing resilient, potent cultivars simultaneously.

Because association mapping identifies genomic neighborhoods rather than single causal genes, the team followed up by searching for candidate genes near the significant SNPs. The list they assembled reads like a who’s who of plant secondary metabolism regulation. Among them stands MYB6, a transcription factor known to activate flavonoid-biosynthetic genes, making it an obvious lever for engineering or selecting plants that produce more glabridin. Another candidate, an OCTOPUS-like gene, plays a role in the differentiation of primary root protophloem and overall root architecture—a fascinating connection, since the metabolites of interest accumulate in specific root tissues, and the internal anatomy of the root may determine where and how much compound is stored.

The candidate list also includes WRKY transcription factors, a large family of regulators that modulate phenylpropanoid, alkaloid, and terpene pathways. WRKY genes are central switches in plant defense signaling, and their presence near the associated loci reinforces the idea that licorice’s medicinal chemistry is deeply entangled with its stress biology. A fourth candidate, aminodeoxychorismate synthase, adds a further layer of metabolic intrigue, hinting that primary metabolism feeds into the specialized chemistry of the root in ways that association mapping can now expose. Together, these genes sketch a plausible molecular chain running from environmental sensing through transcriptional control to the final accumulation of flavonoids in root tissues.

Methodologically, the study demonstrates how modern genomic tools can transform a traditionally understudied medicinal crop. Genotyping-by-sequencing allowed the team to characterize genetic structure and run association mapping in a genus for which genomic resources have been scarce, without requiring a fully assembled reference genome. The combination of population structure analysis, principal component approaches, and mixed linear models for association testing reflects the current best practice for avoiding false positives caused by population stratification—a notorious pitfall when working with geographically structured plant collections such as this one.

The practical implications reach well beyond the laboratory. Wild and landrace licorice populations face pressure from overharvesting and habitat loss, and cultivated varieties often lag behind wild roots in medicinal compound content. By identifying SNP markers linked to glabridin and liquiritigenin accumulation, the study gives breeders molecular tools to screen seedlings for high-value chemistry long before the roots mature—a process that would otherwise take years of cultivation and costly chemical assays. Marker-assisted selection built on these loci could accelerate the development of improved Glycyrrhiza varieties with enhanced medicinal properties, while the genetic structure data can guide the conservation of the species’ most distinctive populations, including the Iranian group highlighted by the analysis.

For a genus that has served human medicine since antiquity, licorice has been surprisingly slow to enter the genomic era. This study changes that, delivering both a comprehensive picture of genetic diversity across Glycyrrhiza species and a concrete set of molecular handles on the chemistry that makes the root valuable. As demand for plant-derived therapeutics grows and climate change tightens the screws on medicinal crop production, the ability to read—and eventually write—the genetic instructions behind licorice’s chemical defenses may prove to be one of the more consequential developments in medicinal plant genomics of the coming decade.

Subject of Research: Genetic structure and SNP associations with secondary metabolites in Glycyrrhiza species and G. glabra

Article Title: Genetic structure analysis of Glycyrrhiza species and identification of SNP-loci associated with secondary metabolites in G. glabra

Article References: Moghadam, A., Karami, A., Kellert, B., Haghi, R., Esmaeili, H., Himmelbach, A., & Otto, L.-G. (2026). Genetic structure analysis of Glycyrrhiza species and identification of SNP-loci associated with secondary metabolites in G. glabra. BMC Genomics, 27(1), Article 767. https://doi.org/10.1186/s12864-026-13361-y

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13361-y

Keywords: licorice, Glycyrrhiza glabra, SNP, genotyping-by-sequencing, GWAS, glabridin, liquiritigenin, flavonoid biosynthesis, genetic diversity, medicinal plants, MYB6, plant breeding

Glycyrrhizin, also known as glycyrrhizinic or glycyrrhizic acid, accumulates in the roots and rhizomes of Glycyrrhiza glabra, the classic liquorice plant, as well as related species such as G. uralensis and G. inflata. On hydrolysis it yields 18β-glycyrrhetinic acid, also called glycyrrhetic acid or enoxolone, which is itself biologically active. The molecule’s commercial and clinical portfolio is remarkably broad. Its monoammonium salts serve as high-intensity sweeteners, and it is the chemical precursor for carbenoxolone, a hemisuccinyl ester derivative with mineralocorticoid activity that is marketed as an antiulcer drug. The review emphasizes that pharmacological studies have documented antiviral activity against hepatitis B and influenza A/H1N1 viruses, anti-inflammatory effects demonstrated through albumin denaturation assays and in ulcerative colitis, anticancer activity in colorectal cancer cell lines SW620 and HT29, and growth suppression of A549 lung adenocarcinoma cells through inhibition of thromboxane synthase.

Clinical evidence further strengthens the case for scaling up production. Glycyrrhizin has been tested alone and in combination therapies for chronic hepatitis C, including in interferon-resistant patients, where injection therapy has been associated with reduced hepatocellular carcinogenesis. A randomized placebo-controlled trial explored glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammatory mechanisms. Against this backdrop of expanding medical relevance, the natural content of glycyrrhizin in even the richest licorice roots remains very low, and wild plants typically need three to four years of growth before harvest, creating a pressing supply problem that the review’s authors set out to address systematically.

Understanding the biosynthetic pathway is the foundation of every enhancement strategy. Glycyrrhetinic acid is an oleanane-type triterpenoid built through the mevalonate pathway from repeated units of isopentenyl pyrophosphate and dimethylallyl pyrophosphate. The pivotal first committed step is the cyclization of 2,3-oxidosqualene into β-amyrin, catalyzed by β-amyrin synthase. From there, sequential oxidation reactions driven mainly by the cytochrome P450 enzymes CYP88D6 and CYP72A154 generate a series of intermediates that culminate in glycyrrhetinic acid. The glycoside is then assembled by glycosyltransferases: UDP-glucose dehydrogenase converts UDP-glucose to UDP-glucuronic acid, and the enzyme UGT73P12 transfers a glucuronic acid moiety to the third carbon of glycyrrhetinic acid, forming glycyrrhetic acid 3-O-mono-β-D-glucuronide, or GAMG. A second glucuronosylation event on GAMG completes glycyrrhizin, with UDP-glucose pyrophosphorylase, known as UGP1, regenerating the UDP-glucose donor.

The most extensively explored strategy for boosting glycyrrhizin is elicitation, in which cultured plant tissues are deliberately stressed with biotic or abiotic agents to switch on secondary metabolism. The earliest in vitro attempt, by Shabani and colleagues in 2009, treated Glycyrrhiza glabra cultures with methyl jasmonate and salicylic acid at concentrations from 0.01 to 2.0 millimolar. Glycyrrhizin peaked at 0.1 millimolar methyl jasmonate after eight hours, while salicylic acid raised content up to 1 millimolar but depressed it at 2 millimolar, an early demonstration that elicitor dose and timing follow narrow windows of benefit. In 2010, Karwasara and colleagues extended the approach to cell cultures of Abrus precatorius, a related legume, finding that culture filtrate of Aspergillus niger at 7.5 percent and dried cell powder of Rhizopus stolonifer at 0.5 percent, together with yeast extract and 50 micromolar ascorbic acid, maximized both biomass and glycyrrhizin accumulation.

Subsequent work has diversified the elicitor toolkit considerably. Srivastava and colleagues subjected Agrobacterium rhizogenes-induced hairy roots of G. glabra to drought-mimicking PEG 6000, the heavy metal cadmium chloride, and the biotic elicitors cellulase and mannan. Polyethylene glycol at 1 percent produced the highest glycyrrhizin after 24 hours, cellulase at 200 micrograms per milliliter progressively raised content over seven days, and remarkably the lowest mannan dose of 10 milligrams per liter yielded the peak concentration of 3.3089 micrograms per milligram after ten days. In Taverniera cuneifolia root cultures, Awad and colleagues screened six fungal and five bacterial elicitors and found that Rhizobium leguminosarum drove glycyrrhizic acid to 6 milligrams per gram, while methyl jasmonate at 100 micromolar delivered a 2.5-fold increase. Jaiswal and colleagues, meanwhile, showed that adenine sulphate outperformed biotin, salicylic acid and polyamines in G. glabra callus, reaching 35.44 micrograms per gram, likely because sulphate assimilation supports amino acid and metabolite synthesis.

Microbial partners and physical stimuli have added further dimensions. Li and colleagues raised glycyrrhizin in adventitious roots of G. uralensis with low-dose salicylic acid, optimal sucrose at 4 percent and one-strength MS salts, and later showed that Aspergillus niger treatments in 5-liter balloon-type bubble bioreactors increased glycyrrhizin up to 200 milligrams per liter of elicitor, though higher doses reversed the effect. Xie and colleagues reported that the plant growth-promoting bacterium Bacillus pumilus, inoculated into drought-stressed G. uralensis plants, reduced antinutritional factors, improved protein digestibility and boosted antioxidants, cumulatively enhancing glycyrrhizin biosynthesis. In G. inflata hairy roots, methyl jasmonate at 100 micromolar produced 5.7 times more glycyrrhizin than controls after five days, whereas chitosan proved ineffective. Allahdou and colleagues found cellulase from Aspergillus niger at 200 micrograms per milliliter optimal for both glycyrrhizin and glycyrrhetinic acid in G. glabra hairy roots, and Afsharzadeh and colleagues combined hairy root transformation with red and blue LED light, recording antioxidant capacity gains over 55 days of exposure. Most strikingly, Yamamoto and colleagues documented overwhelming glycyrrhizin induction through symbiosis with the nitrogen-fixing rhizobium Mesorhizobium sp. J8, which elevated chlorophyll, nitrogenase activity and the expression of genes for glycyrrhizin and jasmonic acid synthesis.

Beyond elicitation, the review highlights genome editing as a fundamentally different lever. Chiyo and colleagues in 2023 used CRISPR/Cas9 in G. uralensis hairy roots to knock out the genes CYP93E3 and CYP72A566, which divert flux toward soyasaponins, along with CYP716A179 for oleanolic acid and LUS1 for betulinic acid. By eliminating these competing branches of β-amyrin metabolism, more precursor was channeled toward glycyrrhetinic acid and ultimately glycyrrhizin. When pathway blocking was paired with overexpression of CYP88D6, the oxidation step toward glycyrrhetinic acid, glycyrrhizin production rose again. Although the absolute gains were modest, the authors note that the results were achieved within a single month of culture, a dramatic contrast to the three to four years required by wild licorice, illustrating how pathway rationalization could compress production timelines.

The third pillar is heterologous biosynthesis in microbes, which began when Zhu and colleagues engineered 11-oxo-β-amyrin and glycyrrhetinic acid synthesis into Saccharomyces cerevisiae in 2017. In 2019, Wang and colleagues integrated codon-optimized CYP88D6 and CYP72A154, together with β-amyrin synthase and an Arabidopsis thaliana NADPH-cytochrome P450 reductase, into the yeast chromosome, producing a strain that yielded 2.5 milligrams per liter of β-amyrin and 14 micrograms per liter of glycyrrhetinic acid. Introducing a cytochrome b5 from G. uralensis multiplied glycyrrhetinic acid output eightfold, and combining both strategies achieved a 40-fold improvement to 0.5 milligrams per liter in batch fermentation, extended to a 630-fold improvement reaching 8.78 milligrams per liter in fed-batch mode. The review cautions that plant P450 enzymes often show reduced catalytic activity in yeast and can interact poorly with reductases, generating reactive oxygen species that impair cell growth and product yield.

Taken together, the review paints a picture of a field converging on integrated solutions. Every elicitation regime, whether chemical, microbial or physical, works by provoking the plant’s in vitro defense machinery, and every approach shows a concentration ceiling beyond which toxicity erases the gains. The glycyrrhizin pathway is multifaceted and compartmentalized, limiting metabolite flux, and many of its genes and regulators remain unknown, while gene editing can sometimes merely redirect accumulation into other unintended metabolites. Even so, the authors conclude that the enhancements already demonstrated carry genuine commercial value, both for glycyrrhizin and its carbenoxolone derivative, and that the same elicitation, editing and engineering playbook is readily transferable to other plant secondary metabolites, positioning licorice biotechnology as a template for the sustainable production of high-value natural products worldwide.

Subject of Research: Biotechnological strategies for enhancing glycyrrhizin biosynthesis in licorice and engineered microbes

Article Title: An overview of strategies used for increasing Glycyrrhizin biosynthesis

Article References: Patil, S. P., Patil, R. R., Kore, S. D., & Raut, M. K. (2026). An overview of strategies used for increasing Glycyrrhizin biosynthesis. Discover Industrial Chemistry and Materials, 1(1), Article 7. https://doi.org/10.1007/s44508-026-00008-9

Image Credits: AI Generated

DOI: 10.1007/s44508-026-00008-9

Keywords: glycyrrhizin, licorice, Glycyrrhiza glabra, elicitation, CRISPR, Saccharomyces cerevisiae, secondary metabolites, metabolic engineering, hairy root cultures, triterpenoid saponin, glycyrrhetinic acid, plant tissue culture

Obesity arises from a complex interplay of genetic predisposition, environmental pressures, and lifestyle factors, culminating in the abnormal accumulation of adipose tissue. At the cellular level, the expansion of fat mass depends on adipogenesis, the process by which precursor cells differentiate into mature adipocytes that store lipid. Interrupting this process has long been a strategic goal for metabolic research, and natural products have increasingly been scrutinized as sources of candidate anti-adipogenic molecules. Glycyrrhiza uralensis, known in traditional medicine for its anti-inflammatory and antioxidant properties, had previously been linked to metabolic effects, but gancaonin N itself had never been examined for its potential to modulate fat cell formation and lipid metabolism.

To close that gap, the research team deployed a two-pronged strategy. First, they used network pharmacology, a computational framework that maps the interactions between bioactive compounds, their molecular targets, and disease-associated genes. By predicting the targets of gancaonin N and intersecting them with genes linked to obesity, the team identified 17 overlapping targets. Enrichment analyses using the Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes pointed toward pathways governing lipid metabolism, adipocyte differentiation, and AMP-activated protein kinase signaling, a central energy-sensing cascade within cells.

Central to these computational predictions were two hub genes with well-documented roles in fat biology: peroxisome proliferator-activated receptor gamma, often described as the master transcriptional regulator of adipocyte differentiation, and fatty acid synthase, the enzyme responsible for de novo lipid synthesis. The network analysis suggested that gancaonin N might act on precisely the molecular machinery that drives cells toward the fat-storing phenotype, setting the stage for laboratory confirmation.

For the experimental phase, the researchers turned to 3T3-L1 preadipocytes, mouse cells that can be reliably driven to differentiate into mature adipocytes using a hormonal cocktail that includes 3-isobutyl-1-methylxanthine, dexamethasone, and insulin, a protocol abbreviated as MDI. This model is a cornerstone of adipogenesis research because it recapitulates, with remarkable fidelity, the transcriptional and morphological changes that accompany fat cell development in living tissue. When the team treated differentiating cells with gancaonin N, the results were striking.

Oil Red O staining, the classic technique that renders accumulated lipid droplets a vivid red, revealed that adipocyte differentiation and lipid accumulation were significantly inhibited in a concentration-dependent manner. In other words, the more gancaonin N the cells received, the less fat they stored. The suppression was not merely cosmetic: molecular analyses at both the protein and messenger RNA levels confirmed a coordinated shutdown of the adipogenic program.

Western blotting and PCR analyses showed downregulation of the key transcription factors that orchestrate adipocyte identity, including PPARγ, CCAAT/enhancer-binding protein alpha, and sterol regulatory element-binding protein 1c. These regulators function as a hierarchical circuit: C/EBPα and PPARγ reinforce each other’s expression to lock cells into the adipocyte fate, while SREBP-1c drives the expression of lipogenic enzymes. Their coordinated suppression indicates that gancaonin N intervenes early and broadly in the differentiation cascade rather than acting on a single downstream node.

The compound also suppressed lipogenic genes such as fatty acid synthase and fatty acid binding protein 4, or FABP4, proteins that equip mature adipocytes to synthesize and store lipid. Perhaps most intriguingly, gancaonin N was associated with activation of AMP-activated protein kinase, a cellular energy sensor that, when switched on, shifts metabolism away from synthesis and storage and toward fatty acid oxidation and energy expenditure. AMPK activation is a mechanism shared by several established metabolic interventions, including exercise and the diabetes drug metformin, which lends mechanistic plausibility to the observed anti-adipogenic effects.

The study’s integrated design deserves attention in its own right. By using network pharmacology to generate hypotheses and then validating them in a controlled cellular system, the researchers demonstrated a workflow that can efficiently triage natural compounds for metabolic activity, potentially accelerating the discovery of anti-obesity agents from the vast repository of traditional medicine. The authors emphasize that gancaonin N appears to regulate adipocyte differentiation and lipid metabolism through multiple signaling pathways simultaneously, a multi-target profile that distinguishes it from single-node approaches.

Important caveats remain. The evidence is confined to a cell culture model, and the journey from inhibited lipid droplets in a petri dish to a clinically meaningful effect on human body weight is long and uncertain, requiring studies in animal models and, eventually, controlled human trials to establish efficacy, bioavailability, and safety. Nevertheless, the identification of a licorice-derived isoflavone that converges on PPARγ, SREBP-1c, and AMPK, three of the most consequential nodes in metabolic regulation, provides a compelling molecular foundation for further exploration. As obesity rates continue to climb globally, compounds like gancaonin N illustrate how ancient pharmacopeias may still yield modern therapeutic insights when subjected to the scrutiny of contemporary molecular science.

The choice of gancaonin N as a study subject reflects a broader trend in pharmacognosy, the discipline that investigates medicines derived from natural sources. Licorice root contains hundreds of structurally diverse secondary metabolites, including glycyrrhizin, flavonoids, chalcones, and isoflavones, many of which carry prenyl side chains. Prenylation, the attachment of a hydrophobic isoprenoid group to a flavonoid scaffold, generally increases a molecule’s lipophilicity and can enhance its affinity for cellular membranes and intracellular protein targets. This structural feature may help explain why prenylated isoflavones from licorice have repeatedly attracted attention in studies of inflammation, cancer biology, and now energy metabolism, since improved membrane permeability can translate into more pronounced activity in cultured cells.

The network pharmacology approach used by the team deserves further explanation for readers unfamiliar with the method. Rather than testing a compound against one presumed target at a time, network pharmacology treats drug action as a web of interactions. Researchers first compile a list of proteins predicted to bind the compound, drawing on databases of known drug-target relationships and structural similarity. They then overlay this list with genes statistically associated with a disease, in this case obesity, and examine where the two sets intersect. The resulting overlap, here 17 shared targets, is subjected to enrichment analysis to determine which biological processes and signaling pathways are overrepresented. This systems-level view acknowledges that most chronic diseases involve dozens of interacting pathways, and that multi-target interventions may better reflect how traditional herbal medicines have historically been understood to act.

The molecular findings also fit into a well-mapped hierarchy of fat cell biology. PPARγ sits at the apex of the adipogenic transcriptional cascade, and its activity is sufficient to drive even non-fat cells toward lipid storage, which is why it has been the target of thiazolidinedione diabetes drugs. Downstream of these transcription factors, FABP4 serves as a cytoplasmic chaperone for fatty acids and is widely used as a marker of mature adipocyte function. Upstream, AMPK acts as a fuel gauge: when cellular energy levels fall, AMPK phosphorylates downstream targets such as acetyl-CoA carboxylase, thereby throttling fatty acid synthesis and promoting oxidation. The observation that gancaonin N both suppresses pro-adipogenic transcription factors and engages this energy-sensing pathway suggests a coordinated mechanism rather than a single point of interference.

The 3T3-L1 model itself has a long pedigree. Derived from mouse embryos in the 1970s, these cells have been used in thousands of studies precisely because their differentiation is robust, reproducible, and amenable to quantitative readouts such as Oil Red O extraction and spectrophotometric measurement. Findings in this system, however, do not automatically translate to human physiology. Human adipocytes differ in gene expression patterns, receptor repertoires, and metabolic flux, and the concentrations of a compound that are achievable in culture medium often far exceed what can be reached in circulating blood after oral ingestion. Absorption, metabolism by liver enzymes, and rapid excretion can all diminish the effective exposure of tissues to a dietary flavonoid.

These considerations frame the appropriate next steps. Animal studies using diet-induced obesity models would test whether gancaonin N or licorice extracts enriched in it can influence weight gain, insulin sensitivity, and adipose tissue morphology in a living organism. Pharmacokinetic profiling would establish whether meaningful plasma concentrations are attainable and whether the compound accumulates in adipose tissue. Safety evaluation is equally essential, since licorice is known to contain constituents with documented physiological effects, and any candidate derived from this plant would need to demonstrate a favorable therapeutic window.

The research was conducted by investigators affiliated with the College of Korean Medicine at Kyung Hee University in Seoul, together with collaborators at the Korea Institute of Science and Technology, and was supported by funding from the Korea Health Industry Development Institute under the Ministry of Health and Welfare of the Republic of Korea. The work was published as an open access article under a Creative Commons Attribution license, received in October 2025 and accepted in August 2026, allowing the scientific community unrestricted access to the methods and data. As with all early-stage findings, the value of this study lies less in immediate application than in the hypothesis it generates: that a defined molecule from a traditional medicinal plant can be traced, target by target, through the molecular circuitry of fat cell formation.

Subject of Research: Anti-adipogenic effects of the licorice-derived compound gancaonin N on adipocyte differentiation and lipid metabolism in 3T3-L1 cells

Article Title: Anti-adipogenic effects of gancaonin N, a bioactive compound from Glycyrrhiza uralensis, in MDI-Induced 3T3-L1 adipocytes

Article References: Kim, S. W., Kwon, S., Jee, W., Kim, N., Kim, M., Byun, D. Y., Kwon, S., Lee, H.-G., Chung, W.-S., & Jang, H.-J. (2026). Anti-adipogenic effects of gancaonin N, a bioactive compound from Glycyrrhiza uralensis, in MDI-Induced 3T3-L1 adipocytes. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05566-1

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05566-1

Keywords: gancaonin N, Glycyrrhiza uralensis, adipogenesis, obesity, lipid metabolism, AMPK signaling, PPARγ, 3T3-L1 adipocytes, network pharmacology, licorice, fatty acid synthase, natural products